|Specializations in Countries
|Contribution to the Global Plan
View this partner's profile
Organization Contact Information
|National Tuberculosis Control Programme,
|Community Health Sciences Unit
|2651753612/ 265 1 757680
|Other Online Presence:
Focal Point Contact Information
|Deputy Programme Manager
|265 1757680 / 265 1 753 612
Alternate Focal Point Contact Information
|265 999 274 228
|Is your organization legally registered in your country:
|If yes, please enter your registration number:
|Organization Type - Primary:
|Organization Type - Secondary:
|A government department responsible for tuberculosis control activities, including registration, treatment, management, data analysis, training and technical guidance.
It is also the responsible for policy formulation, guidance as well as sourcing funding to run TB Control activities in the country
It is the organisation mandated by the Government of Malawi to oversee, direct and advocate for TB control activities.
The organization's plans are to enhance DOTS in all the corners of the country (there is already 100% coverage), to control the development and spread of multi-drug resistant TB and reduce TB/HIV co-infection and promote involvement of other stakeholders.
|Do you know about the UNHLM declaration:
Specializations / Areas of Work
Delivery of health services and care
Funding, including innovative and optimized approach to funding TB Care
Provision of drugs, diagnostics and commodities
Research and Development
Other Organization Information
|Total number of staff in your organization:
|Number of full-time staff who are directly involved with TB:
|Number of part-time staff who are directly involved with TB:
|Number of volunteers who are directly involved with TB:
|How did you hear about the Stop TB Partnership:
Attendance at a TB related event
|If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
|Why do you wish join the Stop TB Partnership:
|Are you a member of a Stop TB national partnership:
|Are you in contact with your national TB programme:
|Please tell us how your organization is contributing to your country's national TB control plan:
|Involves all stakeholders in the generation of the strategic plan
|Which country is your headquarters located in:
|Which countries do you do operate in:
(This includes countries you are conducting activities in)
|Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:
TB Care Delivery:
Since 1990, the country has adapted and adopted DOTS programme and strategies as advanced by the WHO. Since 1984 it has provided data on DOTS centres as they have been expanded from the then 25 to the current 120. In 2006 it adapted a WHO approach of development of an IEC Strategic Plan for expansion of DOTS.
Since 2007 it has provided data to WHO on yearly bases for the surveillance of MDR-TB in Malawi. It carried out a DR-Survey in Malawi in 2010 in order to determine the magnitude of the problem.
In 2008, the NTP developed a TB/HIV collaborative activities plan as advocated by WHO in order to ensure adherence to standards. It provides to WHO yearly data on TB/HIV co-infection in order to monitor treands. It conducted baseline co-infection survey in 2000 and has since routinely reported on TB/HIV coinfection. In 2008 it produced guidelines for TB/HIV collaboration for implementation of the 12 recommended areas of collaboration.
The NTP has contributed towards the expansion of TB laboratory microscopy and following the WHO guidelines on TB laboratory work. It provides guidance and SOPs for laboratory workers. It trains laboratory workers on standard TB microscopy.
In 2010 it introduced the MIGT-960 for the culture and drug sensitivity testing of TB in order to monitor the DR-TB.
In 2011 the NTP introduced the Gene-Expert for rapidly diagnosing TB as well as the estimating Rifampicin resistant in TB/HIV co-infect patients. It is currently being rolled out. In 2011 it also introduced the LED light and Flourecent microscope for the diagnosis of TB in high burden laboratories.
New TB Drugs:
The NTP intends to take part part in any trials involving the development and testing of new TB drugs as and when approved by the WHO in the future.
New TB Vaccines:
It will take part in any WHO approved vaccine trials as and when the research is approved.
It will take part in fundamental research approved by the WHO.
Between 1996 and 2009 the NTP undertook extensive operational research studies which have influenced policy both locally and internationally.
|Declaration of interests:
July 22, 2013